News

Weight-loss medicines are rising in popularity. According to some estimates, this market will be worth $44 billion in risk-adjusted sales by 2030, while it was only valued at $2.5 billion last year

Image source: The Motley Fool.

Dynavax Technologies (NASDAQ: DVAX)Q3 2023 Earnings CallNov 02, 2023, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Geron (NASDAQ: GERN)Q3 2023 Earnings CallNov 02, 2023, 9:00 a.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Karyopharm Therapeutics (NASDAQ: KPTI)Q3 2023 Earnings CallNov 02, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Novavax (NASDAQ: NVAX) is facing some significant headwinds. Its financials aren't in great shape, and its future remains questionable. Investors have been dumping the stock in droves, and it is no

Shares of Ardelyx (NASDAQ: ARDX) were up 9.5% as of 3:47 p.m. after the biotech company announced better-than-expected third-quarter 2023 results.

Ardelyx's quarterly revenue skyrocketed to $56.4

Shares of Coherus Biosciences (NASDAQ: CHRS) closed up 14% on Monday after the company announced the long-awaited approval of its drug, Loqtorzi, by the U.S. Food and Drug Administration (FDA).

In a

When it comes to picking winning biotech companies, sometimes it pays to go with players who are at the cutting edge of their field. On Oct. 18, regulators at the Food and Drug Administration (FDA)

There is no denying that the biotech industry can be pretty risky and volatile, but there are also advantages to investing in stocks in this sector. First, there is always a need for innovative

Hardly for the first time this year, biotech CymaBay Therapeutics (NASDAQ: CBAY) had a winning day on the market Monday. Following the news that its leading drug candidate had been granted an

Cathie Woods, through her various ARK funds, has been scooping up shares of Intellia Therapeutics (NASDAQ: NTLA), Block (NYSE: SQ), and Ginkgo Bioworks (NYSE: DNA) lately. All three stocks have

Shares of Ardelyx (NASDAQ: ARDX) were up 13.2% as of 2:30 p.m. ET Wednesday after the U.S. Food and Drug Administration (FDA) approved its first-in-class chronic kidney disease drug. In a press

If you had bought Novavax's (NASDAQ: NVAX) shares at the beginning of 2020, you'd be sitting on solid gains. The stock skyrocketed soon after the pandemic started as Novavax raced to develop a

Over the course of 2007 to 2021, growth stocks dramatically outperformed value stocks. Historically low interest rates, coupled with the emergence of the knowledge economy, sparked one of the

Novavax (NASDAQ: NVAX) fell behind in the original coronavirus vaccine race as rivals Pfizer and Moderna brought their products to market. The biotech launched its vaccine a year-and-a-half later in

Shares of Ardelyx (NASDAQ: ARDX) were down more than 12% as of 3:30 p.m. on Wednesday. The healthcare company, which has a chronic kidney disease (CKD) drug that is awaiting approval later this

Intellia Therapeutics (NASDAQ: NTLA) has announced a good deal of positive news in recent months, from progress in clinical trials to an expanded partnership with big biotech Regeneron

Gene-editing specialist Intellia Therapeutics (NASDAQ: NTLA) has caught the attention of Cathie Wood. The founder and CEO of Ark Invest, an investment management firm focused on investing in

Shares of Scilex Holdings (NASDAQ: SCLX) were up around 14% as of 2:30 p.m. ET on Monday. The healthcare stock is still down more than 55% this year.

Scilex makes non-opioid pain management products

Early on in the pandemic, Moderna and Pfizer beat smaller rival Novavax (NASDAQ: NVAX) to market with their coronavirus vaccines by a year or more in some countries. This head start offered them the

Shares of Coherus BioSciences (NASDAQ: CHRS) rose 9.4% on Thursday after the biotech resubmitted a biologic license application (BLA) supplement for a key product to the U.S. Food and Drug